AU2006226182C1 - Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer - Google Patents

Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer Download PDF

Info

Publication number
AU2006226182C1
AU2006226182C1 AU2006226182A AU2006226182A AU2006226182C1 AU 2006226182 C1 AU2006226182 C1 AU 2006226182C1 AU 2006226182 A AU2006226182 A AU 2006226182A AU 2006226182 A AU2006226182 A AU 2006226182A AU 2006226182 C1 AU2006226182 C1 AU 2006226182C1
Authority
AU
Australia
Prior art keywords
compound according
treatment
compound
prophylaxis
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006226182A
Other languages
English (en)
Other versions
AU2006226182A1 (en
AU2006226182B2 (en
Inventor
Costantino Congiatu
Christopher Mcguigan
Kenneth Mills
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nucana PLC
Original Assignee
Nucana PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nucana PLC filed Critical Nucana PLC
Publication of AU2006226182A1 publication Critical patent/AU2006226182A1/en
Assigned to CARDIFF PROTIDES LIMITED reassignment CARDIFF PROTIDES LIMITED Request for Assignment Assignors: UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED
Publication of AU2006226182B2 publication Critical patent/AU2006226182B2/en
Application granted granted Critical
Publication of AU2006226182C1 publication Critical patent/AU2006226182C1/en
Assigned to NUCANA BIOMED LIMITED reassignment NUCANA BIOMED LIMITED Request for Assignment Assignors: CARDIFF PROTIDES LIMITED
Assigned to NuCana plc reassignment NuCana plc Request to Amend Deed and Register Assignors: NUCANA BIOMED LIMITED
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2006226182A 2005-03-21 2006-03-16 Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer Ceased AU2006226182C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0505781.5A GB0505781D0 (en) 2005-03-21 2005-03-21 Chemical compounds
GB0505781.5 2005-03-21
PCT/GB2006/000932 WO2006100439A1 (en) 2005-03-21 2006-03-16 Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer

Publications (3)

Publication Number Publication Date
AU2006226182A1 AU2006226182A1 (en) 2006-09-28
AU2006226182B2 AU2006226182B2 (en) 2011-09-01
AU2006226182C1 true AU2006226182C1 (en) 2012-06-14

Family

ID=34531603

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006226182A Ceased AU2006226182C1 (en) 2005-03-21 2006-03-16 Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer

Country Status (20)

Country Link
US (1) US8263575B2 (enExample)
EP (1) EP1866324B1 (enExample)
JP (2) JP5345381B2 (enExample)
CN (2) CN101175763A (enExample)
AT (1) ATE471334T1 (enExample)
AU (1) AU2006226182C1 (enExample)
BR (1) BRPI0609704B8 (enExample)
CA (1) CA2602324C (enExample)
CY (1) CY1111538T1 (enExample)
DE (1) DE602006014949D1 (enExample)
DK (1) DK1866324T3 (enExample)
ES (1) ES2348741T3 (enExample)
GB (1) GB0505781D0 (enExample)
IL (1) IL186104A (enExample)
MX (1) MX2007011666A (enExample)
PL (1) PL1866324T3 (enExample)
PT (1) PT1866324E (enExample)
SI (1) SI1866324T1 (enExample)
WO (1) WO2006100439A1 (enExample)
ZA (1) ZA200709011B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0623493D0 (en) * 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
AU2012216500B2 (en) * 2006-11-24 2013-06-20 Katholieke Universiteit Leuven Nucleoside aryl phosphoramidates and their use as anti-viral agents for the treatment of hepatitis C virus
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
AR074897A1 (es) 2008-12-23 2011-02-23 Pharmasset Inc Fosforamidatos de nucleosidos
CL2009002206A1 (es) 2008-12-23 2011-08-26 Gilead Pharmasset Llc Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
MX2011006890A (es) 2008-12-23 2011-07-20 Pharmasset Inc Analogos de nucleosidos.
BRPI1004575A2 (pt) 2009-01-09 2016-04-05 Inhibitex Inc composto, composição farmacêutica, método de tratamento de infecções virais, método de separação dos diaestereômeros de fósforo
AP2012006535A0 (en) 2010-03-31 2012-10-31 Gilead Pharmasset Llc Stereoselective synthesis of phosphorous containing actives
GB201016855D0 (en) * 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
WO2012092484A2 (en) * 2010-12-29 2012-07-05 Inhibitex, Inc. Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections
US9095599B2 (en) 2011-01-03 2015-08-04 Nanjing Molecular Research, Inc. O-(substituted benzyl) phosphoramidate compounds and therapeutic use
ES2569185T3 (es) 2011-03-01 2016-05-09 Nucana Biomed Limited Derivados de fosforamidato de 5-fluoro-2'-desoxiuridina para uso en el tratamiento del cáncer
US9085599B2 (en) 2011-03-16 2015-07-21 Enanta Pharmaceuticals, Inc. 2′allene-substituted nucleoside derivatives
AU2013346515B2 (en) * 2012-11-16 2017-05-25 NuCana plc Process for preparing nucleoside prodrugs
EP3004130B1 (en) 2013-06-05 2019-08-07 Idenix Pharmaceuticals LLC. 1',4'-thio nucleosides for the treatment of hcv
JP2017504572A (ja) * 2013-11-27 2017-02-09 アイデニクス・ファーマシューティカルズ・エルエルシー 肝臓癌治療のためのヌクレオチド類
US20170101431A1 (en) * 2014-05-28 2017-04-13 Idenix Pharmaceuticals Llc Nucleoside derivatives for the treatment of cancer
AU2015265607A1 (en) * 2014-05-28 2016-11-17 Idenix Pharmaceuticals Llc Nucleoside derivatives for the treatment of cancer
HRP20191461T1 (hr) 2014-11-28 2019-11-15 NuCana plc Novi 2' i/ili 5' derivati 3'-deoksi adenozina supstituirani aminokiselinskim esterom fosforamidata, kao antikancerogenog spoja
FI3265102T3 (fi) 2015-03-06 2025-10-31 Atea Pharmaceuticals Inc Beta-d-2'-deoksi-2'-alfa-fluori-2'-beta-c-substituoituja-2-modifioituja-n6-substituoituja puriininukleotideja hcv-hoitoa varten
EP3377512A4 (en) * 2015-11-16 2019-09-18 Ichorion Therapeutics, Inc. Nucleic Acid PRODRUGS
GB201522764D0 (en) * 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609600D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
GB201609602D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Chemical compounds
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
PT3512863T (pt) 2016-09-07 2022-03-09 Atea Pharmaceuticals Inc Nucleótidos de purina 2'-substituídos-n6-substituídos para tratamento de vírus de rna
WO2018071675A1 (en) * 2016-10-12 2018-04-19 Georgetown University Cd99 inhibitors and their uses
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201715011D0 (en) 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis
GB201720279D0 (en) 2017-12-05 2018-01-17 Nucana Biomed Ltd Anticancer compounds
JP2020164521A (ja) * 2019-03-29 2020-10-08 国立大学法人 長崎大学 抗ウィルス薬
GB201904544D0 (en) 2019-04-01 2019-05-15 NuCana plc Anticancer compounds
WO2021173713A1 (en) 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
CN113549076B (zh) * 2021-07-23 2022-12-06 中国药科大学 一种多取代嘌呤类化合物及其制备方法和应用
WO2026151964A1 (en) 2025-01-10 2026-07-16 Atea Pharmaceuticals, Inc. Compositions and use thereof in treating hepatitis e infections with beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR880000094B1 (ko) 1984-12-07 1988-02-23 보령제약 주식회사 뉴클레오시드 유도체의 제조방법
CA2004695C (en) 1988-12-12 1999-08-10 Rosanne Bonjouklian Phospholipid nucleosides
DE4418690A1 (de) * 1994-05-28 1996-01-11 Boehringer Mannheim Gmbh Neue Lipidester von Nucleosid-Monophosphaten und deren Verwendung als immunsuppressive Arzneimittel
GB9505025D0 (en) * 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
EP0821692B1 (en) 1995-04-21 2006-01-11 University Of South Florida Immunopotentiating inosine monophosphate 5'-nucleotidase resistant derivatives and uses thereof
JP3761958B2 (ja) 1996-03-12 2006-03-29 彰 松田 ３′−カルバモイルアルキルヌクレオシド誘導体
ES2172303T3 (es) * 1998-01-23 2002-09-16 Newbiotics Inc Agentes terapeuticos obtenidos por catalisis enzimatica.
GB9821058D0 (en) * 1998-09-28 1998-11-18 Univ Cardiff Chemical compound
JP4768909B2 (ja) 2000-09-29 2011-09-07 扶桑薬品工業株式会社 トポイソメラーゼ阻害剤
US20030073618A1 (en) * 2001-02-08 2003-04-17 Kozhemyakin Leonid A. Compounds comprising disulfide-containing peptides and nitrogenous bases, and medical uses thereof
DE10108851A1 (de) * 2001-02-23 2002-09-12 Resprotect Gmbh Verwendung von 5'-substituierten Nukleosiden und/oder deren Prodrugs zur resistenzfreien Therapie von Infektionskrankheiten
WO2003000200A2 (en) * 2001-06-22 2003-01-03 Pharmasset Ltd. β-2'-OR 3'-HALONUCLEOSIDES
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
GB0401088D0 (en) * 2004-01-19 2004-02-18 Univ Cardiff Phosphoramidate derivatives
US20070265222A1 (en) * 2004-06-24 2007-11-15 Maccoss Malcolm Nucleoside Aryl Phosphoramidates for the Treatment of Rna-Dependent Rna Viral Infection
CN101287472B (zh) * 2005-08-15 2011-10-12 弗·哈夫曼-拉罗切有限公司 抗病毒的4'-取代前核苷酸的氨基磷酸酯类化合物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FU HUA ET AL: "Reaction of ADP with amino acid methyl esters mediated by trimethylsilyl chloride." CHEMICAL COMMUNICATIONS (CAMBRIDGE, ENGLAND) 7 JAN 2003, no. 1, 7 January 2003 (2003-01-07), pages 134-135 *
FU, HUA ET AL: "Electrospray ionization mass spectra of amino acid phosphoramidates of adenosine" RAPID COMMUNICATIONS IN MASS SPECTROMETRY , 14(19), 1813-1822 *
GRIFFITH, T. M. et al: "Enhanced inhibition of the EDHF phenomenon by a phenyl methoxyalaninyl phosphoramidate derivative of dideoxyadenosine", British J. Pharmacology, 2004, 142, 27-30. *
IVNOVSKAYA M. G. et al: Modification of Oligo(poly)nucleotide phosphomonoester groups in aqueous solutions", Nucleosides & Nucleotides, 1987, 6(5), 913-934. *

Also Published As

Publication number Publication date
JP2008533191A (ja) 2008-08-21
DE602006014949D1 (de) 2010-07-29
CN101175763A (zh) 2008-05-07
US8263575B2 (en) 2012-09-11
BRPI0609704A2 (pt) 2010-04-20
BRPI0609704B8 (pt) 2021-09-28
CA2602324A1 (en) 2006-09-28
CY1111538T1 (el) 2015-08-05
IL186104A (en) 2013-06-27
AU2006226182A1 (en) 2006-09-28
ATE471334T1 (de) 2010-07-15
ES2348741T3 (es) 2010-12-13
US20090215715A1 (en) 2009-08-27
AU2006226182B2 (en) 2011-09-01
IL186104A0 (en) 2008-01-20
JP5863702B2 (ja) 2016-02-17
PL1866324T3 (pl) 2010-12-31
GB0505781D0 (en) 2005-04-27
WO2006100439A1 (en) 2006-09-28
EP1866324A1 (en) 2007-12-19
BRPI0609704B1 (pt) 2020-12-01
PT1866324E (pt) 2010-09-16
JP2013173786A (ja) 2013-09-05
JP5345381B2 (ja) 2013-11-20
CA2602324C (en) 2015-02-24
ZA200709011B (en) 2009-01-28
MX2007011666A (es) 2007-11-14
SI1866324T1 (sl) 2010-10-29
DK1866324T3 (da) 2010-09-27
CN103936807A (zh) 2014-07-23
EP1866324B1 (en) 2010-06-16

Similar Documents

Publication Publication Date Title
AU2006226182B2 (en) Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer
US9321798B2 (en) Phosphoramidite derivatives of gemcitabine for use in the treatment of cancer
RU2464272C2 (ru) Арилфосфорамидаты нуклеозида и их применение в качестве противовирусных средств для лечения вирусного гепатита с
EP3235824B1 (en) Mixture of rp/sp gemcitabine-[phenyl-(benzyloxy-l-alaninyl)]-phosphate
FI93217B (fi) Menetelmä terapeuttisesti aktiivisten nukleosidijohdannaisten estereiden ja amidien valmistamiseksi
US20110015147A1 (en) Anti-viral pyrimidine nucleoside analogues
JPH10503220A (ja) 置換カンプトテシン誘導体およびその製造方法
JPH07101976A (ja) 制癌剤
HK1230204A1 (en) Mixture of rp/sp gemcitabine-[phenyl-(benzyloxy-l-alaninyl)]-phosphate
HK1230204B (en) Mixture of rp/sp gemcitabine-[phenyl-(benzyloxy-l-alaninyl)]-phosphate
HK1161265A (en) Nucleoside aryl phosphoramidates and their use as anti-viral agents for the treatment of hepatitis c virus

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: CARDIFF PROTIDES LIMITED

Free format text: FORMER APPLICANT(S): UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 12 JAN 2012.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 12 JAN 2012

PC1 Assignment before grant (sect. 113)

Owner name: NUCANA BIOMED LIMITED

Free format text: FORMER APPLICANT(S): CARDIFF PROTIDES LIMITED

FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: NUCANA PLC

Free format text: FORMER NAME(S): NUCANA BIOMED LIMITED

MK14 Patent ceased section 143(a) (annual fees not paid) or expired